Tribune News Service
New Delhi, May 8
The Ministry of Defence on Saturday said Drugs Controller General of India’s (DCGI) has granted permission for emergency use for drug as therapy to treat Covid-19 cases.
An anti-COVID-19 application of the drug called 2-DG has been okayed for adjunct therapy in moderate to severe COVID-19 patients.
Being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty in the country, the Ministry of Defence said.
It has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad.
Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence.
Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients, a MoD statement said.
The drug comes in powder form in sachet, which is taken orally by dissolving it in water. It accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virally infected cells.
DRDO took the initiative of developing anti-COVID therapeutic application of 2-DG.
In April 2020, during the first wave of the pandemic, INMAS-DRDO scientists conducted laboratory experiments with the help of Centre for Cellular and Molecular Biology (CCMB), Hyderabad and found that this molecule works effectively against SARS-CoV-2 virus and inhibits the viral growth. Based on these results, Central Drugs Standard Control Organization (CDSCO) permitted Phase-II clinical trial of 2-DG in COVID-19 patients in May 2020.
In Phase-II trials during May to October 2020, the drug was found to be safe in COVID-19 patients and showed significant improvement in their recovery.
Phase II-A was conducted in six hospitals and Phase II-B clinical trial was conducted at 11 hospitals all over the country. Phase-II trial was conducted on 110 patients.
DCGI further permitted the Phase-III clinical trials in November 2020. The Phase-III clinical trial was conducted on 220 patients between December 2020 to March 2021 at 27 COVID hospitals in Delhi, Uttar Pradesh, West Bengal, Gujarat, Rajasthan, Maharashtra, Andhra Pradesh, Telangana, Karnataka and Tamil Nadu. The detailed data of phase-III clinical trial was presented to DCGI.
Disclaimer: This post has not been edited by our staff and is published from a syndicated feed. The Original Source of this post can be found at Source link